GBA Presents: RADIO SAVANT-!

stonedinvestor said:
This an older upgrade but same high PT and same pointing towards this QTR for an update.

Granted there is no guarantee that it will be successful. The TAM here is rather large.

Dice Therapeutics initiated with a Buy at H.C. Wainwright 07/18 DICE H.C. Wainwright analyst Emily Bodnar initiated coverage of Dice Therapeutics with a Buy rating and $40 price target. Dice's DELSCAPE technology platform is meant to enable the company to create oral small molecules against historically difficult to target protein-protein interactions, Bodnar tells investors in a research note. The analyst sees "significant upside potential" if efficacy and safety data are positive in the Q3 data update.
More...
The Diceman!

 
I respect Adam F alot he went very negative.

I also have along long history with this Co they are a shade shady.
The CEO talks very freely.

Today's breathless news-
CEL-SCI says Multikine reduced and eliminated tumors 08:52 CVM CEL-SCI Corporation issued the following letter to its shareholders. "The Phase 3 study of our investigational cancer immunotherapy, Multikine , was the largest advanced primary head and neck cancer study ever conducted. We built a full-scale manufacturing facility and spent 10 years and over $100M because we were convinced that our Multikine could help these very sick patients. Our successful results are unprecedented for a disease that has not seen a survival benefit from treatment in decades. Multikine Reduced and Eliminated Tumors Within Three Weeks and Before Surgery The most important result of our study is this: 16% of Multikine patients in the radiation-only group in our Phase 3 study had at least a 30% tumor reduction within just a few weeks of treatment before surgery. Five of these responders had their tumors completely disappear before surgery. Think about that for a minute. These patients presented with advanced primary disease, and within three weeks of Multikine treatment, before surgery, their tumors were gone. "

Over a week ago CEL-SCI's Multikine 'not getting approved,' STAT's Feuerstein says 08/19 CVM STAT's Adam Feuerstein said via Twitter: $CVM posted results from Multikine ph3 study on clinicaltrials less thandotgreater than gov today, confirming the failure. Median Overall Survival: Multikine 46.3 months; Placebo 52.9 months. Placebo patients lived longer. This drug is not getting approved, anywhere...Also, $CVM incessant hand-waving about a Multikine benefit observed in lower-risk patients is a non-starter. The analysis was post-hoc data mining and will be thrown out by any regulatory agency that sees it. If Cel-Sci actually files, ever..." Shares of CEL-SCI are up 9% to $4.60 in midday trading. Reference Link Show Related Items >>
 
Going a good deal higher-- Start making a list of companies over their 200 & 50 day.....
and put SQM on it! Going to $111+

Sociedad Química y Minera de Chile S.A. (SQM)
NYSE - Nasdaq Real Time Price.
104.48+0.77 (+0.74%)
 
WATCH-DIS

Disney (DIS) is gearing up this week to unveil what's in store for the media and entertainment conglomerate with its Disney+ Day on Thursday and D23 Expo later in the week. Disney stock rose early Wednesday.

Look for the Disney+ Day to update investors and fans alike on the company's streaming slate, including the much-anticipated debut of "Marvel's Thor: Love and Thunder" and the Sept. 8 premiere of the live-action version of the classic "Pinocchio," starring Tom Hanks as Gepetto.

An ad-free Disney+ subscription is set to increase to $10.99 a month from $7.99 in November. That's no surprise, considering an industrywide subscription growth slowdown amid soaring production costs for new content. Disney also will introduce an ad-supported, lower-priced tier, something rival Netflix (NFLX) also is working on.

Meanwhile, Disney's multiday D23 Expo will feature presentations on its media businesses, theme parks and cruises, with product reveals and sneak peeks. The event runs from Sept. 9 to 11.
 
stonedinvestor said:
POSSIBLE GUMMY #2---> NBEV
NewAge files patent on new anti-aging discovery 06:05 NBEV NewAge announced the discovery of a new method of action to fight the effects of aging and the filing of a new patent to protect the uniqueness of the discovery. Following publication in the Journal of Biosciences and Medicine of the recent discovery on how to block spike proteins from binding to human cells, NewAge scientists have filed for a patent that contains multiple unique claims, and a new discovery that supports cardiovascular health and anti-aging. The new discovery encapsulated in the patent includes a powerful new way to unblock the secretion signal from the hypothalamus, thereby stimulating the anterior pituitary gland to naturally secrete human growth hormone.One of the major contributors to aging and the decline in cardiovascular health is the increase in the production of dipeptidyl-peptidase 4. DPP4 acts a signal to the anterior pituitary and it degrades over time as humans biologically age. With a new combination of natural ingredients including Tahitian NONI fruit and pterostilbene, NewAge scientists have developed a method of action to unblock the DPP4 signal by 99.1% and allow the secretion from the hypothalamus to the anterior pituitary, thereby triggering the body to naturally regulate itself and secrete growth hormone, as it did when the body was in growth and development mode versus in the aging process.

"
More...
>>>> Well Stoney.... it's $0.09 now. :mad:

GBA UPGRADE>>>> ATXG $5.82
It was $600 last week. :D
 
You must log in or register to reply here.
Back
Top